**Amendments to the Claims**:

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-28 (canceled):

Claim 29 (currently amended): A peptide having the structure:



$Z^1$- $X^6$-$X^7$-$X^8$-$X^9$-$X^{10}$-$X^{11}$-$X^{12}$-$X^{13}$-$X^{14}$-$X^{15}$-$X^{16}$-$X^{17}$- $Z^2$

wherein $X^6$ is selected from the group consisting of: D-arginine, D- alanine, D-norleucine, D-α-aminobutyric acid, D-valine, D-leucine, D-isoleucine, D- proline, D-methionine, D- phenylalanine, D- asparagine, D-glutamine, D- serine, D-threonine, D- glutamic acid, D-aspartic acid, D- lysine, D-histidine, D-tryptophan, D-tyrosine, D-cyclohexylalanine, D-(2')naphthylalanine, D-ornithine, D-homoarginine, D-nitroarginine, D-norarginine, D-citrulline and 5-guanidinopropionic acid,

$X^7$ is cysteine,

$X^8$ is either methionine, norleucine, or N-methyl norleucine,

$X^9$ is leucine,

$X^{10}$ is either is either asparagine, glutamine, leucine, isoleucine, valine, norleucine, cyclohexylalanine, phenylalanine, (2')-naphthylalanine, tyrosine, histidine, tryptophan, lysine, serine, threonine, methionine, or citrulline,

$X^{11}$ is arginine,

$X^{12}$ is valine,

$X^{13}$ is phenylalanine, (2')napthylalanine, p-fluoro-phenylalanine, tyrosine, or cyclohexylalanine,

$X^{14}$ is arginine or alanine,

$X^{15}$ is either proline or sarcosine,

$X^{16}$ is cysteine or D-cysteine,

$X^{17}$ is an optionally present amino acid that, if present, is either tryptophan or tyrosine,

$Z^1$ is an optionally present protecting group that, if present, is covalently joined to the N-terminal amino group,

$Z^2$ is an optionally present protecting group that, if present, is covalently joined to the C-terminal carboxy group,

wherein ~~a substituent~~ said peptide optionally contains ~~on said peptide is optionally substituted with~~ a detectable label,
or a pharmaceutically acceptable salt of said peptide.

Claim 30 (previously presented): The peptide of claim 29, wherein said detectable label is selected from the group consisting of: a luminescent label, an enzymatic label, and a radiolabel.

Claim 31 (previously presented): The peptide of claim 30, wherein said detectable label is not present.

Claim 32 (previously presented): The peptide of claim 30, wherein $X^6$ is either D-arginine, D-alanine, D-norleucine, D-proline, D-phenylalanine, D-asparagine, D-serine, D-glutamic acid, D-lysine, or D-citrulline.

Claim 33 (currently amended): The peptide of claim 32, wherein $X^{10}$ is glutamine ~~or arginine~~.

Claim 34 (previously presented): The peptide of claim 33, wherein said peptide is substituted with a radiolabel.

Claim 35 (previously presented): The peptide of claim 33, wherein said peptide is not substituted with a detectable label.

Claim 36 (previously presented): The peptide of claim 31, wherein $X^{17}$ is not present, $Z^1$ is $-C(O)CH_3$ and $Z^2$ is $-NH_2$.

Claim 37 (previously presented): The peptide of claim 33, wherein $X^{17}$ is not present, $Z^1$ is $-C(O)CH_3$ and $Z^2$ is $-NH_2$.

Claim 38 (previously presented): The peptide of claim 29, wherein said peptide consists of a sequence selected from the group consisting of: SEQ ID NOs: 29, 30, 31, 32, 33, and 34.

Claim 39 (previously presented): The peptide of claim 29, wherein said peptide consists of SEQ ID NO: 30.

Claim 40 (currently amended): A method of screening for a compound able to bind MCH-1R comprising the step of measuring the ability of said compound to inhibit binding of a detectably labeled peptide of claim 29 to MCH-1R by measuring the change in detectable label.

Claim 41 (previously presented): The method of claim 40, wherein said peptide is radiolabeled.